Vaxcyte, Inc.
PCVX
Hisse Senetlerindeki Sıralama
#2023
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Hisse Fiyatı
$66.25
Piyasa Değeri
$10.16B
Değişim (1 gün)
0.02%
Değişim (1 yıl)
56.42%
Ülke
US
Ticaret Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Vaxcyte, Inc. (PCVX) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $65.70 - 2026-10-01
Gün sonu en düşük fiyat: $32.16 - 2020-06-01
Gün sonu en düşük fiyat: $32.16 - 2020-06-01
Vaxcyte, Inc. için hisse fiyatı geçmişi: 2020 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 18.85% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $516.45 | 21.16% |
US
|
|
| $246.94 | 798.28% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $883.64 | 5.86% |
NL
|
|
| $752.14 | 7.30% |
CH
|
